Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01569659 · ClinicalTrials.gov registry record · Phase 4
High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia
A Phase 4 study of Schizophrenia, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 4
- Development phase
- 101
- Enrollment target
- 2
- Study locations
NCT01569659 is a Phase 4 study of Schizophrenia that has completed, run by Northwestern University. The registered enrollment target is 101 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (54% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01569659, a Phase 4 study of Schizophrenia, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 101 participants
- Enrollment target
- 2
- Study locations
Study Summary
The aim of this study is to compare the efficacy of a flexible high dose of lurasidone to a standard dose of lurasidone in patients with treatment resistant schizophrenia or schizoaffective disorder. Efficacy of both dosage groups will be measured through testing of positive symptoms and other components of psychopathology (negative symptoms, general psychopathology, anxiety, depression, cognitive function, global function, severity of illness and tolerability). Patients must qualify for treatment resistance after two or more antipsychotic drug trials to be included in this trial.
Conditions Studied
Interventions
- DRUG Lurasidone
Study Locations (2)
Illinois
- Northwestern University Department of Psychiatry and Behavioral Sciences - Chicago
- Northwestern University Psychiatric Clinical Research Program - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01569659
The ClinicalTrials.gov registry entry for NCT01569659 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (54% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Lurasidone is the first listed.
NCT01569659 reports 2 study locations spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT01569659 about?
NCT01569659 is a clinical study titled "High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia". The aim of this study is to compare the efficacy of a flexible high dose of lurasidone to a standard dose of lurasidone in patients with treatment resistant schizophrenia or schizoaffective disorder. Efficacy of both dosage groups will be measured through testing of positive symptoms and other compo...
What is the current status of trial NCT01569659?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 101 participants. The study started on 2011-10. Estimated completion is 2015-07.
What conditions does trial NCT01569659 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT01569659?
The interventions under investigation include: Lurasidone (DRUG).
Who is sponsoring clinical trial NCT01569659?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01569659 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.